PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21437074-4 2010 Sitagliptin has in several clinical studies been shown to improve metabolic control in type 2 diabetes, both when used as monotherapy and when used in combination with metformin, sulfonylurea, thiazolidinediones or insulin. Sitagliptin Phosphate 0-11 insulin Homo sapiens 215-222 18372550-0 2008 [Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes]. Sitagliptin Phosphate 1-13 insulin Homo sapiens 56-63 19366777-14 2009 In this group, 2 patients regained insulin independence after treatment with sitagliptin, which was associated with increase in C-peptide levels. Sitagliptin Phosphate 77-88 insulin Homo sapiens 35-42 23745054-7 2008 Hypoglycemia due to off-label combinations with insulin and sitagliptin may be prevented by reducing meal-time insulin doses. Sitagliptin Phosphate 60-71 insulin Homo sapiens 111-118 18182122-8 2008 Markers of beta-cell function (HOMA-beta and proinsulin/insulin ratio) were improved with sitagliptin treatment. Sitagliptin Phosphate 90-101 insulin Homo sapiens 45-55 18182122-8 2008 Markers of beta-cell function (HOMA-beta and proinsulin/insulin ratio) were improved with sitagliptin treatment. Sitagliptin Phosphate 90-101 insulin Homo sapiens 48-55 20092585-15 2010 CONCLUSION: In this 24-week study, the addition of sitagliptin to ongoing, stable-dose insulin therapy with or without concomitant metformin improved glycaemic control and was generally well tolerated in patients with type 2 diabetes. Sitagliptin Phosphate 51-62 insulin Homo sapiens 87-94 18201579-6 2007 RESULTS: By inhibiting DPP-4, sitagliptin enhances postprandial levels of active glucagon-like peptide-1 (GLP-1), leading to a rise in insulin release and decrease in glucagon secretion from pancreatic alpha-cells. Sitagliptin Phosphate 30-41 insulin Homo sapiens 135-142 18201579-11 2007 Markers of beta-cell function, including proinsulin/insulin ratio and homeostasis model assessment of beta-cell function, were improved with sitagliptin treatment. Sitagliptin Phosphate 141-152 insulin Homo sapiens 41-51 18201579-11 2007 Markers of beta-cell function, including proinsulin/insulin ratio and homeostasis model assessment of beta-cell function, were improved with sitagliptin treatment. Sitagliptin Phosphate 141-152 insulin Homo sapiens 44-51 34883184-1 2022 AIMS: To evaluate glycemic variations, changes in insulin resistance and oxidative stress after chiglitazar or sitagliptin treatment in untreated patients with type 2 diabetes mellitus (T2DM). Sitagliptin Phosphate 111-122 insulin Homo sapiens 50-57 16912128-11 2006 RESULTS: Sitagliptin dose-dependently inhibited plasma DPP-4 activity over 24 h, enhanced active GLP-1 and GIP levels, increased insulin/C-peptide, decreased glucagon, and reduced glycemic excursion after OGTTs administered at 2 and 24 h after single oral 25- or 200-mg doses of sitagliptin. Sitagliptin Phosphate 9-20 insulin Homo sapiens 129-136 16912128-11 2006 RESULTS: Sitagliptin dose-dependently inhibited plasma DPP-4 activity over 24 h, enhanced active GLP-1 and GIP levels, increased insulin/C-peptide, decreased glucagon, and reduced glycemic excursion after OGTTs administered at 2 and 24 h after single oral 25- or 200-mg doses of sitagliptin. Sitagliptin Phosphate 9-20 insulin Homo sapiens 137-146 17157112-17 2006 Significant reductions in fasting serum proinsulin levels and the proinsulin/insulin ratio were seen with sitagliptin treatment compared with placebo (both, P < 0.01). Sitagliptin Phosphate 106-117 insulin Homo sapiens 40-50 17157112-17 2006 Significant reductions in fasting serum proinsulin levels and the proinsulin/insulin ratio were seen with sitagliptin treatment compared with placebo (both, P < 0.01). Sitagliptin Phosphate 106-117 insulin Homo sapiens 66-76 17157112-17 2006 Significant reductions in fasting serum proinsulin levels and the proinsulin/insulin ratio were seen with sitagliptin treatment compared with placebo (both, P < 0.01). Sitagliptin Phosphate 106-117 insulin Homo sapiens 43-50 17352516-3 2007 In large, well designed phase III trials in patients with type 2 diabetes mellitus, sitagliptin 100 or 200mg once daily alone or in combination with other antihyperglycaemics was associated with significant improvements relative to placebo in overall glycaemic control and indices for insulin response and beta-cell function. Sitagliptin Phosphate 84-95 insulin Homo sapiens 285-292 17130196-7 2006 Homeostasis model assessment of beta-cell function and proinsulin-to-insulin ratio improved with sitagliptin. Sitagliptin Phosphate 97-108 insulin Homo sapiens 55-65 17130196-7 2006 Homeostasis model assessment of beta-cell function and proinsulin-to-insulin ratio improved with sitagliptin. Sitagliptin Phosphate 97-108 insulin Homo sapiens 58-65 34779103-1 2022 OBJECTIVE: To assess the efficacy and safety of sitagliptin in youth with type 2 diabetes (T2D) inadequately controlled with metformin +- insulin. Sitagliptin Phosphate 48-59 insulin Homo sapiens 138-145 33464705-0 2021 An adult patient with permanent neonatal diabetes successfully discontinued insulin therapy after initiating sitagliptin added to sulphonylurea. Sitagliptin Phosphate 109-120 insulin Homo sapiens 76-83 34114012-1 2021 "Islet function and insulin sensitivity in latent autoimmune diabetes in adults taking sitagliptin: A randomized trial ". Sitagliptin Phosphate 87-98 insulin Homo sapiens 20-27 34406395-7 2021 CONCLUSIONS: In glucose intolerant PI-CF, sitagliptin intervention augmented meal-related incretin responses with improved early insulin secretion and glucagon suppression without affecting postprandial glycemia. Sitagliptin Phosphate 42-53 insulin Homo sapiens 129-136 35551683-6 2022 The sitagliptin treatment also improved the insulinogenic index (+86%) and the insulin/glucose (+25%), glucagon-like peptide-1/glucose (+46%) incremental area under the curves. Sitagliptin Phosphate 4-15 insulin Homo sapiens 79-86 35527084-0 2022 Corrigendum to "Effect of chiglitazar and sitagliptin on glucose variations, insulin resistance and inflammatory-related biomarkers in untreated patients with type 2 diabetes" (Diabetes Res. Sitagliptin Phosphate 42-53 insulin Homo sapiens 77-84 35169165-10 2022 However, insulin clearance showed some differences between sitagliptin and metformin treatment (p < 0.02). Sitagliptin Phosphate 59-70 insulin Homo sapiens 9-16 34114619-1 2021 "Islet function and insulin sensitivity in latent autoimmune diabetes in adults taking sitagliptin: A randomized trial". Sitagliptin Phosphate 87-98 insulin Homo sapiens 20-27 35395243-8 2022 SIGNIFICANCE: The combined use of sitagliptin and insulin significantly improved the cardioprotective effect of insulin and prevented the early cardiac dysfunction in STZ diabetic rats. Sitagliptin Phosphate 34-45 insulin Homo sapiens 112-119 35547000-0 2022 Comparative Evaluation of Chiglitazar and Sitagliptin on the Levels of Retinol-Binding Protein 4 and Its Correlation With Insulin Resistance in Patients With Type 2 Diabetes. Sitagliptin Phosphate 42-53 insulin Homo sapiens 122-129 35445591-8 2022 Sitagliptin and insulin treatment lowered hemoglobin A1c (HbA1c, WMD = -0.36, 95% CI: -0.61 to -0.10; I2 = 91.6%), increased fasting C-peptide (FCP, WMD = 0.08, 95% CI: -0.02 to 0.17; I2 = 88.8%), and had fewer adverse events compared with insulin alone. Sitagliptin Phosphate 0-11 insulin Homo sapiens 133-142 35445591-8 2022 Sitagliptin and insulin treatment lowered hemoglobin A1c (HbA1c, WMD = -0.36, 95% CI: -0.61 to -0.10; I2 = 91.6%), increased fasting C-peptide (FCP, WMD = 0.08, 95% CI: -0.02 to 0.17; I2 = 88.8%), and had fewer adverse events compared with insulin alone. Sitagliptin Phosphate 0-11 insulin Homo sapiens 240-247 33241550-15 2021 3) Good glycemic efficacy of sitagliptin is medicated through reduced insulin resistance as well as enhanced beta-cell functions. Sitagliptin Phosphate 29-40 insulin Homo sapiens 70-77 33258801-6 2021 The oral administration of either GABA or Sita ameliorated blood glucose levels, increased transplanted human beta-cell counts and plasma human insulin levels. Sitagliptin Phosphate 42-46 insulin Homo sapiens 144-151 33140566-8 2021 There were no differences on insulin requirements in the ICU; however, sitagliptin therapy was associated with lower mean daily insulin requirements (21 1+-18 4 vs 32 5+-26 3 units, p=0 007) after transition to regular floor compared to placebo. Sitagliptin Phosphate 71-82 insulin Homo sapiens 128-135 33140566-10 2021 Sitagliptin therapy was associated with lower mean daily insulin requirements after transition to regular floors. Sitagliptin Phosphate 0-11 insulin Homo sapiens 57-64 32606870-0 2020 Sitagliptin Increases Beta-Cell Function and Decreases Insulin Resistance in Newly Diagnosed Vietnamese Patients with Type 2 Diabetes Mellitus. Sitagliptin Phosphate 0-11 insulin Homo sapiens 55-62 32994187-2 2020 RESEARCH DESIGN AND METHODS: In a multicenter, case-control, retrospective, observational study, sitagliptin, an oral and highly selective dipeptidyl peptidase 4 inhibitor, was added to standard of care (e.g., insulin administration) at the time of hospitalization in patients with type 2 diabetes who were hospitalized with COVID-19. Sitagliptin Phosphate 97-108 insulin Homo sapiens 210-217 33224612-0 2020 Evaluation of the use of sitagliptin for insulin resistance in burn patients. Sitagliptin Phosphate 25-36 insulin Homo sapiens 41-48 33224612-3 2020 Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that improves glycemic control by slowing the inactivation of incretin hormones, increasing insulin synthesis and release from pancreatic beta cells and lowering glucagon secretion from pancreatic alpha cells. Sitagliptin Phosphate 0-11 insulin Homo sapiens 150-157 33224612-4 2020 The objective of this study was to describe our institution"s experience with using sitagliptin to help mitigate insulin resistance after burn injury. Sitagliptin Phosphate 84-95 insulin Homo sapiens 113-120 33224612-11 2020 In the 3 days after sitagliptin was started, exogenous insulin requirements significantly decreased to a median to 36.3 units per day (IQR 11.7, 95) (P=0.009). Sitagliptin Phosphate 20-31 insulin Homo sapiens 55-62 33224612-13 2020 After sitagliptin was started, it took a median of 3 days (IQR 2, 3.25) to be liberated from the insulin infusion. Sitagliptin Phosphate 6-17 insulin Homo sapiens 97-104 33224612-15 2020 CONCLUSION: The addition of sitagliptin to burn patients" medication regimens significantly reduced insulin requirements over a 3-day period and allowed liberation from insulin drips. Sitagliptin Phosphate 28-39 insulin Homo sapiens 100-107 33224612-15 2020 CONCLUSION: The addition of sitagliptin to burn patients" medication regimens significantly reduced insulin requirements over a 3-day period and allowed liberation from insulin drips. Sitagliptin Phosphate 28-39 insulin Homo sapiens 169-176 32606870-1 2020 Introduction: To investigate effects of Sitagliptin on the enhancement of beta-cell function, reducing insulin resistance, serum glucagon like peptide-1 (GLP-1) concentrations and blood glucose in patients with type 2 diabetes mellitus (T2D) and suggest one of the underlying mechanisms on beta-cell function and insulin resistance. Sitagliptin Phosphate 40-51 insulin Homo sapiens 103-110 32606870-7 2020 After treatment with Sitagliptin 100 mg/day, they achieved significant improvements in beta-cell function, peripheral insulin sensitivity and insulin resistance. Sitagliptin Phosphate 21-32 insulin Homo sapiens 118-125 32606870-7 2020 After treatment with Sitagliptin 100 mg/day, they achieved significant improvements in beta-cell function, peripheral insulin sensitivity and insulin resistance. Sitagliptin Phosphate 21-32 insulin Homo sapiens 142-149 32606870-9 2020 Conclusion: Sitagliptin improved beta-cell function, insulin resistance and blood glucose in newly diagnosed patients with T2D. Sitagliptin Phosphate 12-23 insulin Homo sapiens 53-60 32240122-0 2020 Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients. Sitagliptin Phosphate 29-40 insulin Homo sapiens 44-51 32240122-1 2020 BACKGROUND The current study aimed to compare the effects of dapagliflozin and sitagliptin on insulin resistant and body fat distribution in newly diagnosed type 2 diabetic patients. Sitagliptin Phosphate 79-90 insulin Homo sapiens 94-101 32240122-9 2020 CONCLUSIONS Dapagliflozin and sitagliptin had comparable effects on improving insulin resistant and blood glucose control, and these benefits may be associated with improvement of systemic inflammation. Sitagliptin Phosphate 30-41 insulin Homo sapiens 78-85 30393950-10 2019 CONCLUSION: When initiating insulin glargine therapy, continuation of sitagliptin, compared with discontinuation, resulted in a clinically meaningful greater reduction in HbA1c without an increase in hypoglycaemia. Sitagliptin Phosphate 70-81 insulin Homo sapiens 28-35 32095182-3 2020 As both IHL and FM are known as associating factors of insulin resistance, these reductions may lead to improvement of insulin sensitivity, which in turn may contribute to sitagliptin-induced amelioration of glycemic control. Sitagliptin Phosphate 172-183 insulin Homo sapiens 55-62 32095182-3 2020 As both IHL and FM are known as associating factors of insulin resistance, these reductions may lead to improvement of insulin sensitivity, which in turn may contribute to sitagliptin-induced amelioration of glycemic control. Sitagliptin Phosphate 172-183 insulin Homo sapiens 119-126 31405334-0 2019 Metformin and sitagliptin combination therapy ameliorates polycystic ovary syndrome with insulin resistance through upregulation of lncRNA H19. Sitagliptin Phosphate 14-25 insulin Homo sapiens 89-96 31019624-0 2019 Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study. Sitagliptin Phosphate 30-41 insulin Homo sapiens 73-80 30393950-0 2019 Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study. Sitagliptin Phosphate 142-153 insulin Homo sapiens 170-177 30393950-1 2019 AIMS: To compare the effects of continuing versus discontinuing sitagliptin when initiating and intensively titrating insulin glargine. Sitagliptin Phosphate 64-75 insulin Homo sapiens 118-125 32231757-0 2020 A Study of Seasonal Variation in the Effect of Add-On Sitagliptin on Blood Glucose Control in Insulin-Treated Patients With Type 2 Diabetes. Sitagliptin Phosphate 54-65 insulin Homo sapiens 94-101 32231757-2 2020 Methods: Using data collected from 630 patients in a multicenter study, we compared the amount of change in HbA1c after 1, 3, 6, 9, and 12 months of add-on administration of sitagliptin in insulin-treated patients divided into four groups based on the month when sitagliptin was started. Sitagliptin Phosphate 174-185 insulin Homo sapiens 189-196 31543976-6 2019 Treatment with sitagliptin resulted in lower BG levels prior to surgery (101+-mg/dL vs 107+-13 mg/dL, p=0.01); however, there were no differences in the mean BG concentration, proportion of patients who developed stress hyperglycemia (21% vs 22%, p>0.99), length of hospital stay, rate of perioperative complications and need for insulin therapy in the intensive care unit or during the hospital stay. Sitagliptin Phosphate 15-26 insulin Homo sapiens 330-337 30178570-0 2019 Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with premixed insulin. Sitagliptin Phosphate 23-34 insulin Homo sapiens 125-132 31019624-1 2019 Background: Sitagliptin, the first dipeptidyl peptidase-4 inhibitor, has demonstrated efficacy and safety as monotherapy and as add-on therapy to oral antidiabetic agents or insulin. Sitagliptin Phosphate 12-23 insulin Homo sapiens 174-181 31019624-15 2019 Conclusions: Despite baseline differences in demographic factors and medications, sitagliptin showed good efficacy and safety in all age groups of patients receiving it as add-on therapy to insulin during routine management of T2DM. Sitagliptin Phosphate 82-93 insulin Homo sapiens 190-197 30178570-3 2019 At week 24, the between-group difference (sitagliptin - placebo) in the least squares mean (95% confidence intervals) change from baseline in HbA1c in patients using premixed insulin was -0.43% (-0.58, -0.28), P <0.001. Sitagliptin Phosphate 42-53 insulin Homo sapiens 175-182 29138226-0 2018 Insulin secretory effect of sitagliptin: assessment with a hyperglycemic clamp combined with a meal challenge. Sitagliptin Phosphate 28-39 insulin Homo sapiens 0-7 29893003-7 2018 Increases in homeostatic model assessment of beta-cell function and decreases in proinsulin-to-insulin ratio were greater in the sitagliptin group. Sitagliptin Phosphate 129-140 insulin Homo sapiens 84-91 29227575-4 2018 Sitagliptin increased standardized insulin secretion, in both healthy and T2D subjects, compared to placebo, but without increasing beta-cell glucose sensitivity. Sitagliptin Phosphate 0-11 insulin Homo sapiens 35-42 30815579-10 2019 Sitagliptin did not impact rates of severe hypoglycaemia, but delayed progression to insulin when added to metformin or metformin/SU regimens. Sitagliptin Phosphate 0-11 insulin Homo sapiens 85-92 30815579-12 2019 Sitagliptin was associated with lower HbA1c, without increased risk for severe hypoglycaemia and was associated with delayed progression to insulin when added to metformin with or without SU. Sitagliptin Phosphate 0-11 insulin Homo sapiens 140-147 29208515-8 2018 Meal tolerance testing 3 months after oral sitagliptin, compared to before starting treatment, showed reductions in both early postprandial hyperglycemia and insulin hypersecretion. Sitagliptin Phosphate 43-54 insulin Homo sapiens 158-165 28892258-0 2018 Sitagliptin and Roux-en-Y gastric bypass modulate insulin secretion via regulation of intra-islet PYY. Sitagliptin Phosphate 0-11 insulin Homo sapiens 50-57 28929327-0 2017 Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S). Sitagliptin Phosphate 31-42 insulin Homo sapiens 148-155 28982699-2 2017 RESEARCH DESIGN AND METHODS: This 24-week, controlled, open-label study randomized T2DM patients (n = 440) receiving a stable dose of metformin and insulin combination therapy to sitagliptin (100 mg) or glimepiride (1-3 mg) as add-on therapy. Sitagliptin Phosphate 179-190 insulin Homo sapiens 148-155 28982699-8 2017 CONCLUSIONS: Sitagliptin (100 mg), when compared to glimepiride (1-3 mg), bestowed beneficial effects to T2DM patients in terms of achieving greater glycemic control and also brought significant reductions in total daily dose of insulin required, bodyweight, BMI and hypoglycemic events. Sitagliptin Phosphate 13-24 insulin Homo sapiens 229-236 28933039-0 2017 Dose-Dependent Effect of Sitagliptin on Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Post Hoc Analysis. Sitagliptin Phosphate 25-36 insulin Homo sapiens 116-123 28933039-10 2017 CONCLUSIONS: Addition of sitagliptin to insulin therapy might attenuate the progression of atherosclerosis in patients with T2DM in a dose-dependent manner. Sitagliptin Phosphate 25-36 insulin Homo sapiens 40-47 28829491-0 2017 The effect of sitagliptin on obese patients with insulin treatment-induced diabetes mellitus. Sitagliptin Phosphate 14-25 insulin Homo sapiens 49-56 28829491-1 2017 OBJECTIVE: The objective of the present study was to observe the effect of sitagliptin on obese patients with insulin treatment-induced diabetes mellitus. Sitagliptin Phosphate 75-86 insulin Homo sapiens 110-117 28420697-1 2017 Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE). Sitagliptin Phosphate 0-11 insulin Homo sapiens 77-84 28829491-9 2017 CONCLUSIONS: Sitagliptin can reduce BMI and the occurrence of hypoglycemia in obese patients with insulin treatment-induced diabetes mellitus, and the effect may be related to decreased HOMA-IR, decreased leptin and visfatin levels, and increased adiponectin levels. Sitagliptin Phosphate 13-24 insulin Homo sapiens 98-105 28516377-0 2017 The Influence of Sitagliptin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Prespecified Sub-Analysis. Sitagliptin Phosphate 17-28 insulin Homo sapiens 118-125 28516377-12 2017 CONCLUSIONS: Our data suggest that sitagliptin added to insulin treatment was comparable to other treatments in terms of its impact on treatment-related QOL. Sitagliptin Phosphate 35-46 insulin Homo sapiens 56-63 27255431-0 2017 Efficacy and safety of coadministration of sitagliptin with insulin glargine in type 2 diabetes. Sitagliptin Phosphate 43-54 insulin Homo sapiens 60-67 28213841-0 2017 Sitagliptin down-regulates retinol-binding protein 4 and reduces insulin resistance in gestational diabetes mellitus: a randomized and double-blind trial. Sitagliptin Phosphate 0-11 insulin Homo sapiens 65-72 28213841-3 2017 We investigated the effectiveness of sitagliptin on insulin sensitivity parameters in GDM patients. Sitagliptin Phosphate 37-48 insulin Homo sapiens 52-59 28213841-8 2017 Serum levels of RBP-4 were also markedly decreased in the sitagliptin treatment group, and more importantly it was positively correlated with improved insulin resistance parameters. Sitagliptin Phosphate 58-69 insulin Homo sapiens 151-158 28213841-9 2017 Our study supports a potentially promising role of sitagliptin in improving insulin resistance by decreasing RBP-4 in GDM-affected women. Sitagliptin Phosphate 51-62 insulin Homo sapiens 76-83 27740719-0 2017 Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes. Sitagliptin Phosphate 0-11 insulin Homo sapiens 28-35 27740719-11 2017 CONCLUSIONS: After 24 weeks, sitagliptin added to stable insulin therapy (+-metformin) was generally well tolerated and improved glycemic control in Chinese patients with type 2 diabetes mellitus. Sitagliptin Phosphate 29-40 insulin Homo sapiens 57-64 27882107-13 2016 Sitagliptin phosphate combined with metformin effectively and safely improves glycemic excursion and carbohydrate metabolism in NEDM patients by promoting the first phase of insulin and incretin secretion and inhibiting glucagon secretion of. Sitagliptin Phosphate 0-21 insulin Homo sapiens 174-181 28761576-9 2017 In addition, a marker of vascular-specific inflammation, pentraxin-3, and a marker of beta-cell function (proinsulin/insulin ratio), respectively, were lower after treatment with sitagliptin for 3 months than at baseline (1.88 [0.78]-1.65 [0.63] ng/mL [P = 0.0038] and 0.20 [0.14]-0.17 [0.11] [P = 0.01], respectively). Sitagliptin Phosphate 179-190 insulin Homo sapiens 106-116 28761576-9 2017 In addition, a marker of vascular-specific inflammation, pentraxin-3, and a marker of beta-cell function (proinsulin/insulin ratio), respectively, were lower after treatment with sitagliptin for 3 months than at baseline (1.88 [0.78]-1.65 [0.63] ng/mL [P = 0.0038] and 0.20 [0.14]-0.17 [0.11] [P = 0.01], respectively). Sitagliptin Phosphate 179-190 insulin Homo sapiens 109-116 28056430-6 2017 However, the number of patients that required reduced insulin dose was significantly higher in the sitagliptin group (p=0.01). Sitagliptin Phosphate 99-110 insulin Homo sapiens 54-61 28056430-7 2017 Sitagliptin therapy was associated with an increase in the Mini-Mental State Examination (MMSE) scores (p=0.034); patients without AD receiving only sitagliptin or insulin showed higher MMSE scores as compared to the patients receiving metformin alone (p=0.024). Sitagliptin Phosphate 0-11 insulin Homo sapiens 164-171 28056430-9 2017 CONCLUSION: Besides its effects similar to those of insulin and metformin in glycemic control and in reducing need for insulin, 6-month sitagliptin therapy may also associated with improvement of cognitive function in elderly diabetic patients with and without AD. Sitagliptin Phosphate 136-147 insulin Homo sapiens 119-126 27300579-9 2016 CONCLUSIONS: Vildagliptin and sitagliptin affected incretin hormones, glucose concentrations, insulin and glucagon secretion in a similar manner. Sitagliptin Phosphate 30-41 insulin Homo sapiens 94-101 27087519-3 2017 We tested the hypothesis that pantoprazole plus sitagliptin, would restore insulin independence in islet transplant recipients with early graft insufficiency and determined whether this would persist after a 3-month washout. Sitagliptin Phosphate 48-59 insulin Homo sapiens 75-82 27087519-11 2017 CONCLUSIONS: Sitagliptin plus pantoprazole is well tolerated and safe and may restore insulin independence in some islet transplant recipients with early graft insufficiency, but this was not sustained when treatment was withdrawn. Sitagliptin Phosphate 13-24 insulin Homo sapiens 86-93 28250768-3 2017 The present study aimed to clarify whether sitagliptin, DPP-4 inhibitor, could regress carotid intima-media thickness (IMT) in insulin-treated patients with type 2 diabetes mellitus (T2DM). Sitagliptin Phosphate 43-54 insulin Homo sapiens 127-134 28250768-5 2017 This is an exploratory analysis of a randomized trial in which we investigated the effect of sitagliptin on the progression of carotid IMT in insulin-treated patients with T2DM. Sitagliptin Phosphate 93-104 insulin Homo sapiens 142-149 27409676-7 2016 Older age, longer diabetes duration, male sex, and use of insulin, sulfonylurea, calcium channel blockers, aspirin, ticlopidine, clopidogrel and dipyridamole were significantly associated with a higher risk in sitagliptin users, but dyslipidemia and use of metformin and statin were protective. Sitagliptin Phosphate 210-221 insulin Homo sapiens 58-65 29652465-0 2016 The effect of combination therapy of insulin glargine, metformin, and sitagliptin on insulin secretion, insulin resistance, and metabolic parameters in obese subjects with type 2 diabetes. Sitagliptin Phosphate 70-81 insulin Homo sapiens 85-92 29652465-12 2016 Conclusion: Sitagliptin can improve diabetes control and induce modest weight loss in obese subjectspoorly controlled on insulin glargine and metformin. Sitagliptin Phosphate 12-23 insulin Homo sapiens 121-128 27321385-2 2016 Patients receiving standard doses of sitagliptin plus insulin may require increased doses of sitagliptin or switching to vildagliptin to improve blood glucose control. Sitagliptin Phosphate 93-104 insulin Homo sapiens 54-61 27330133-1 2016 Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial. Sitagliptin Phosphate 0-11 insulin Homo sapiens 77-84 27491324-6 2016 The combination of metformin and sitagliptin, targeting both characteristics of prediabetes (insulin resistance and progressive beta cell degeneration), may potentially slow or halt the progression from prediabetes to type 2 DM. Sitagliptin Phosphate 33-44 insulin Homo sapiens 93-100 27330134-1 2016 Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial. Sitagliptin Phosphate 0-11 insulin Homo sapiens 77-84 27114254-0 2016 Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus. Sitagliptin Phosphate 63-74 insulin Homo sapiens 79-86 27114254-1 2016 INTRODUCTION: A 12-week prospective study was previously performed to assess the effect of add-on therapy with sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with type 2 diabetes mellitus (T2DM) receiving insulin treatment. Sitagliptin Phosphate 111-122 insulin Homo sapiens 227-234 27114254-9 2016 CONCLUSIONS: In Japanese patients with T2DM receiving insulin treatment, add-on therapy with sitagliptin was not associated with weight gain and allowed for the reduction of the insulin dosage. Sitagliptin Phosphate 93-104 insulin Homo sapiens 54-61 27114254-9 2016 CONCLUSIONS: In Japanese patients with T2DM receiving insulin treatment, add-on therapy with sitagliptin was not associated with weight gain and allowed for the reduction of the insulin dosage. Sitagliptin Phosphate 93-104 insulin Homo sapiens 178-185 27222674-1 2016 BACKGROUND: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is an effective oral antidiabetic agent as both monotherapy and when combined with insulin. Sitagliptin Phosphate 12-23 insulin Homo sapiens 144-151 26822324-0 2016 Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial. Sitagliptin Phosphate 0-11 insulin Homo sapiens 77-84 26822324-8 2016 CONCLUSIONS: Sitagliptin attenuated the progression of carotid IMT in insulin-treated patients with T2DM free of apparent cardiovascular disease compared with conventional treatment. Sitagliptin Phosphate 13-24 insulin Homo sapiens 70-77 28035286-12 2016 LEARNING POINTS: The use of sitagliptin and vitamin D3 in patients with new-onset type 1 diabetes mellitus (T1DM) may help decrease the daily insulin requirement by delaying beta cell loss and improving endogenous insulin production.The use of sitagliptin and vitamin D3 in new-onset T1DM could help regulate the imbalance between Th17 and Treg cells.Age 14 years or above, absence of ketoacidosis and positive C-peptide levels in patients with T1DM are good criteria to predict prolonged T1DM remission.The determination of anti-GAD antibodies and C-peptide levels could be helpful in the follow-up of patients in use of sitagliptin and vitamin D3, which could be associated with prolonged T1DM clinical remission. Sitagliptin Phosphate 28-39 insulin Homo sapiens 142-149 26283275-3 2015 OBJECTIVE: To determine whether improved insulin sensitivity and beta-cell function during treatment with sitagliptin is related to lower cortisol levels and/or improved regulation of IGFBP-1 in patients with recent acute coronary syndrome (ACS) and newly discovered glucose abnormalities. Sitagliptin Phosphate 106-117 insulin Homo sapiens 41-48 28035286-12 2016 LEARNING POINTS: The use of sitagliptin and vitamin D3 in patients with new-onset type 1 diabetes mellitus (T1DM) may help decrease the daily insulin requirement by delaying beta cell loss and improving endogenous insulin production.The use of sitagliptin and vitamin D3 in new-onset T1DM could help regulate the imbalance between Th17 and Treg cells.Age 14 years or above, absence of ketoacidosis and positive C-peptide levels in patients with T1DM are good criteria to predict prolonged T1DM remission.The determination of anti-GAD antibodies and C-peptide levels could be helpful in the follow-up of patients in use of sitagliptin and vitamin D3, which could be associated with prolonged T1DM clinical remission. Sitagliptin Phosphate 28-39 insulin Homo sapiens 214-221 26195265-6 2015 Indicators of pancreatic beta-cell function, including proinsulin to insulin ratio and homeostasis model assessment of beta-cell function, were significantly improved in the sitagliptin group, but not in the SU group. Sitagliptin Phosphate 174-185 insulin Homo sapiens 55-65 26195265-6 2015 Indicators of pancreatic beta-cell function, including proinsulin to insulin ratio and homeostasis model assessment of beta-cell function, were significantly improved in the sitagliptin group, but not in the SU group. Sitagliptin Phosphate 174-185 insulin Homo sapiens 58-65 25677642-0 2015 A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes. Sitagliptin Phosphate 73-84 insulin Homo sapiens 118-125 25962401-0 2015 Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy. Sitagliptin Phosphate 80-91 insulin Homo sapiens 15-22 25962401-6 2015 Kaplan-Meier analysis showed that sitagliptin users had a lower risk of insulin initiation compared with sulphonylurea users (p = 0.003), with 26.6% of sitagliptin users initiating insulin versus 34.1% of sulphonylurea users over 6 years. Sitagliptin Phosphate 34-45 insulin Homo sapiens 72-79 25962401-8 2015 Conditional logistic regression analyses confirmed that sitagliptin users were less likely to initiate insulin compared with sulphonylurea users [odds ratios for years 1-6: 0.77, 0.79, 0.81, 0.57, 0.29 and 0.75, respectively (p < 0.05 for years 4 and 5)]. Sitagliptin Phosphate 56-67 insulin Homo sapiens 103-110 26211947-10 2015 In conclusion, sitagliptin seems to maintain its positive effects on glycemia and fasting plasma insulin on the long term. Sitagliptin Phosphate 15-26 insulin Homo sapiens 97-104 26541842-6 2015 The patients had significantly lower glucose variability indices, lower daily insulin requirement and hemoglobin A1c in the group of sitagliptin plus insulin (P<0.01). Sitagliptin Phosphate 133-144 insulin Homo sapiens 78-85 26336611-0 2015 Sitagliptin versus mitiglinide switched from mealtime dosing of a rapid-acting insulin analog in patients with type 2 diabetes: a randomized, parallel-group study. Sitagliptin Phosphate 0-11 insulin Homo sapiens 79-86 26336611-10 2015 Total insulin doses/body weight predicted changes in HbA1c only in the sitagliptin group, but not in the mitiglinide group. Sitagliptin Phosphate 71-82 insulin Homo sapiens 6-13 26336611-11 2015 Use of >0.27 IU/kg of a rapid-acting insulin analog predicted an increase in HbA1c after switching to sitagliptin. Sitagliptin Phosphate 105-116 insulin Homo sapiens 40-47 26336611-14 2015 Additional therapy to sitagliptin or mitiglinide is clearly required to obtain equivalent glycemic control in patients using a higher dose of insulin. Sitagliptin Phosphate 22-33 insulin Homo sapiens 142-149 26301196-0 2015 Effects of 6-Month Sitagliptin Treatment on Insulin and Glucagon Responses in Korean Patients with Type 2 Diabetes Mellitus. Sitagliptin Phosphate 19-30 insulin Homo sapiens 44-51 26124906-10 2015 CONCLUSIONS: These results emphasize the importance of a higher HbA1c at the commencement of sitagliptin therapy in patients on insulin. Sitagliptin Phosphate 93-104 insulin Homo sapiens 128-135 26124906-12 2015 Sitagliptin can be used concomitantly with insulin irrespective of the insulin regimen, duration of insulin treatment, and concomitant medications. Sitagliptin Phosphate 0-11 insulin Homo sapiens 43-50 26055217-11 2015 CONCLUSION: These results showed that sitagliptin and alpha-GIs, miglitol more so than acarbose, improved hyperglycemia in patients with T2DM after single administration, and had different effects on insulin and incretin secretion. Sitagliptin Phosphate 38-49 insulin Homo sapiens 200-207 25795273-0 2015 C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetes. Sitagliptin Phosphate 94-105 insulin Homo sapiens 0-9 25795273-1 2015 AIMS: This retrospective study aimed to determine the hypoglycaemic effect of 2 years of sitagliptin administration in terms of changes in HbA1c and C-peptide immunoreactivity (CPR) index (plasma CPR [ng/mL]/glucose [mg/dL]x100). Sitagliptin Phosphate 89-100 insulin Homo sapiens 149-158 25667364-12 2015 CONCLUSION: Early treatment of hyperglycemia after PT with a DPP-4 inhibitor such as sitagliptin prolongs the time to insulin therapy compared with a standard observation approach. Sitagliptin Phosphate 85-96 insulin Homo sapiens 118-125 25816296-6 2015 RESULTS: Adding sitagliptin to insulin significantly reduced HbA1c from 7.9 +- 1.0% at baseline to 7.0 +- 0.8% at week 24 (P <0.0001), while there was no significant change in HbA1c in the Insulin group (7.8 +- 0.7% vs. 7.8 +- 1.1%, P = 0.32). Sitagliptin Phosphate 16-27 insulin Homo sapiens 192-199 25820927-0 2015 A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine. Sitagliptin Phosphate 88-99 insulin Homo sapiens 126-133 25820927-1 2015 INTRODUCTION: The objective of this study was to assess the effect of sitagliptin on insulin dose in patients with inadequately controlled type 2 diabetes who titrate basal insulin to a target fasting glucose level after initiating sitagliptin. Sitagliptin Phosphate 70-81 insulin Homo sapiens 85-92 25820927-1 2015 INTRODUCTION: The objective of this study was to assess the effect of sitagliptin on insulin dose in patients with inadequately controlled type 2 diabetes who titrate basal insulin to a target fasting glucose level after initiating sitagliptin. Sitagliptin Phosphate 70-81 insulin Homo sapiens 173-180 25820927-5 2015 RESULTS: The increase from baseline in the daily dose of insulin was less in the sitagliptin group (N = 329) compared to placebo (N = 329) (between group difference = -4.7 IU [95% confidence interval [CI] -8.3, -1.2]; p = 0.009). Sitagliptin Phosphate 81-92 insulin Homo sapiens 57-64 25820927-8 2015 CONCLUSION: Administration of sitagliptin prior to intensive titration of basal insulin glargine reduces the insulin dose requirement while providing superior glycemic control and less hypoglycemia, compared to an insulin-only regimen. Sitagliptin Phosphate 30-41 insulin Homo sapiens 109-116 25820927-8 2015 CONCLUSION: Administration of sitagliptin prior to intensive titration of basal insulin glargine reduces the insulin dose requirement while providing superior glycemic control and less hypoglycemia, compared to an insulin-only regimen. Sitagliptin Phosphate 30-41 insulin Homo sapiens 109-116 25388434-4 2015 RESULTS: In response to intraduodenal glucose infusion, heart rate (treatment effect: P = 0.001) and serum insulin concentration (treatment x time interaction: P = 0.041) were higher after sitagliptin treatment than placebo, without a significant difference in blood pressure, plasma glucagon or glucose. Sitagliptin Phosphate 189-200 insulin Homo sapiens 107-114 25325279-7 2015 In a multivariate logistic regression analysis, a high homeostasis model assessment of insulin resistance and low baseline HbA1c level were independent predictors of an HbA1c <=7% after switching to sitagliptin. Sitagliptin Phosphate 202-213 insulin Homo sapiens 87-94 25325279-9 2015 Patients with dominant insulin resistance may be good candidates for switching from a sulfonylurea to sitagliptin to reduce hypoglycemia. Sitagliptin Phosphate 102-113 insulin Homo sapiens 23-30 25816296-12 2015 CONCLUSION: Adding sitagliptin to insulin reduced HbA1c without weight gain or increase in hypoglycemia, and improved treatment satisfaction in Japanese patients with T2DM who were suboptimally controlled despite at least twice daily injection of insulin. Sitagliptin Phosphate 19-30 insulin Homo sapiens 247-254 25328079-0 2015 Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes. Sitagliptin Phosphate 12-23 insulin Homo sapiens 40-47 25328079-11 2015 Our data indicate that sitagliptin and metformin exert different effects on islet hormone secretion in Japanese type 2 diabetic patients on insulin monotherapy. Sitagliptin Phosphate 23-34 insulin Homo sapiens 140-147 25328079-12 2015 A glucagon suppressing effect of sitagliptin could be one of the factors improving blood glucose control in patients inadequately controlled with insulin therapy. Sitagliptin Phosphate 33-44 insulin Homo sapiens 146-153 25328079-0 2015 Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes. Sitagliptin Phosphate 12-23 insulin Homo sapiens 116-123 25328079-1 2015 This study aimed to explore the effects of the dipeptidyl peptidase-4 inhibitor sitagliptin and the biguanide metformin on the secretion of insulin and glucagon, as well as incretin levels, in Japanese subjects with type 2 diabetes mellitus poorly controlled with insulin monotherapy. Sitagliptin Phosphate 80-91 insulin Homo sapiens 140-147 25420579-0 2014 Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data. Sitagliptin Phosphate 64-75 insulin Homo sapiens 96-103 25420579-2 2014 To assess its antidiabetic potency, we used meal tolerance tests (MTTs) to determine the very short-term effects of sitagliptin on plasma concentrations of insulin and glucagon. Sitagliptin Phosphate 116-127 insulin Homo sapiens 156-163 25040945-11 2014 Sitagliptin-induced glycaemic improvement was associated with reductions in BCAA and alpha-HB excursions and better NEFA suppression, in parallel with improved insulin sensitivity, confirming that alpha-HB is a readout of metabolic overload. Sitagliptin Phosphate 0-11 insulin Homo sapiens 160-167 25151573-1 2014 PURPOSE: In the EASIE (Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-Naive Patients) trial, insulin glargine found a significant reduction in glycosylated hemoglobin compared with sitagliptin in patients with type 2 diabetes who are inadequately controlled with metformin. Sitagliptin Phosphate 61-72 insulin Homo sapiens 107-114 25151573-1 2014 PURPOSE: In the EASIE (Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-Naive Patients) trial, insulin glargine found a significant reduction in glycosylated hemoglobin compared with sitagliptin in patients with type 2 diabetes who are inadequately controlled with metformin. Sitagliptin Phosphate 195-206 insulin Homo sapiens 107-114 24949654-9 2014 CONCLUSIONS: Adding once-daily insulin glulisine was more effective in controlling the glycemic fluctuation in Japanese type 2 diabetes patients treated with insulin glargine together with sitagliptin. Sitagliptin Phosphate 189-200 insulin Homo sapiens 31-38 25411623-0 2014 Short- and long-term effect of sitagliptin after near normalization of glycemic control with insulin in poorly controlled Japanese type 2 diabetic patients. Sitagliptin Phosphate 31-42 insulin Homo sapiens 93-100 24949654-0 2014 Efficacy of adding once-daily insulin glulisine in Japanese type 2 diabetes patients treated with insulin glargine and sitagliptin. Sitagliptin Phosphate 119-130 insulin Homo sapiens 30-37 25411623-6 2014 RESULTS: After 1-week sitagliptin treatment, the area under the curve of insulin was markedly increased, and the area under the curve of glucagon and glucose was markedly decreased. Sitagliptin Phosphate 22-33 insulin Homo sapiens 73-80 25411623-7 2014 Duration of diabetes and insulin secretory capacity were correlated with the effect of sitagliptin. Sitagliptin Phosphate 87-98 insulin Homo sapiens 25-32 25411623-8 2014 Furthermore, interestingly, near normalization of glycemic control with insulin therapy for 1-2 weeks brought out the long-term effectiveness of sitagliptin on glucose tolerance for 24 weeks, which was not observed with other antidiabetic drugs. Sitagliptin Phosphate 145-156 insulin Homo sapiens 72-79 25411623-9 2014 CONCLUSIONS: These findings suggest that near normalization of glycemic control with insulin improves the clinical response to sitagliptin in poorly controlled type 2 diabetic patients. Sitagliptin Phosphate 127-138 insulin Homo sapiens 85-92 27419209-0 2014 Adding of Sitagliptin on Insulin Therapy Effectively and Safely Reduces a Hemoglobin A1c Level and Glucose Fluctuation in Japanese Patients with Type 2 Diabetes. Sitagliptin Phosphate 10-21 insulin Homo sapiens 25-32 27419209-13 2014 Add-on of sitagliptin to ongoing insulin therapy effectively reduced either HbA1c level or glucose fluctuation and could be a practical and well-tolerated alternative to treat Japanese patients with type 2 diabetes who had been inadequately controlled by insulin with or without other OHAs. Sitagliptin Phosphate 10-21 insulin Homo sapiens 33-40 27419209-13 2014 Add-on of sitagliptin to ongoing insulin therapy effectively reduced either HbA1c level or glucose fluctuation and could be a practical and well-tolerated alternative to treat Japanese patients with type 2 diabetes who had been inadequately controlled by insulin with or without other OHAs. Sitagliptin Phosphate 10-21 insulin Homo sapiens 255-262 24186866-0 2014 Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose. Sitagliptin Phosphate 11-22 insulin Homo sapiens 71-78 24628303-5 2014 Furthermore, the combination of LPZ and SITA improved glucose tolerance additively, with higher plasma insulin and C-peptide levels compared with SITA-treated mice. Sitagliptin Phosphate 40-44 insulin Homo sapiens 103-110 24628303-6 2014 Similarly, in human in the OGTT, the combination showed significant improvement in glucose-lowering and insulin increase vs SITA-treated group. Sitagliptin Phosphate 124-128 insulin Homo sapiens 104-111 24888256-0 2014 Sitagliptin Improves the Impaired Acute Insulin Response during a Meal Tolerance Test in Japanese Patients with Type 2 Diabetes Mellitus: A Small-Scale Real-World Study. Sitagliptin Phosphate 0-11 insulin Homo sapiens 40-47 23039403-0 2014 Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. Sitagliptin Phosphate 0-11 insulin Homo sapiens 61-68 23039403-5 2014 Regarding insulin resistance, sitagliptin decreased FPI by -8.3% and HOMA-IR by -20.0%, confirming that what have been already reported in short-term studies can be applied also after 2 years of treatment. Sitagliptin Phosphate 30-41 insulin Homo sapiens 10-17 23039403-8 2014 Sitagliptin proved to be effective on glycemic profile and insulin resistance even after 2 years of therapy and to be effective in improving body weight and lipid profile. Sitagliptin Phosphate 0-11 insulin Homo sapiens 59-66 24452849-9 2014 RESULTS: The median (IQR) first- and second-phase insulin secretion responses increased significantly by 56.3% (45.2-112.6%, P = 0.005) and 39.3% (26.5-81.0%, P = 0.006), respectively, following sitagliptin treatment as compared with no sitagliptin treatment. Sitagliptin Phosphate 195-206 insulin Homo sapiens 50-57 24452849-9 2014 RESULTS: The median (IQR) first- and second-phase insulin secretion responses increased significantly by 56.3% (45.2-112.6%, P = 0.005) and 39.3% (26.5-81.0%, P = 0.006), respectively, following sitagliptin treatment as compared with no sitagliptin treatment. Sitagliptin Phosphate 237-248 insulin Homo sapiens 50-57 24888256-3 2014 Therefore, we evaluated the effects of sitagliptin on the acute insulin responses in Japanese patients with type 2 diabetes mellitus (T2DM) using meal tolerance tests. Sitagliptin Phosphate 39-50 insulin Homo sapiens 64-71 24888256-8 2014 RESULTS: Sitagliptin significantly decreased the plasma glucose levels at 60, 120, and 180 min, and significantly increased the plasma insulin levels at 0 and 30 min. Sitagliptin Phosphate 9-20 insulin Homo sapiens 135-142 24432999-11 2014 CONCLUSIONS: LADA patients treated with sitagliptin and insulin maintained beta-cell function by comparison with insulin alone. Sitagliptin Phosphate 40-51 insulin Homo sapiens 113-120 24843761-9 2014 Plasma insulin and glucagon secretion at week 12 were significantly lower than at baseline in the sitagliptin group. Sitagliptin Phosphate 98-109 insulin Homo sapiens 7-14 24607023-4 2014 The aim of the present ongoing study is to assess the effects of sitagliptin on the progression of atherosclerosis in patients with insulin-treated T2DM using carotid intima-media thickness (IMT), an established marker of cardiovascular disease. Sitagliptin Phosphate 65-76 insulin Homo sapiens 132-139 24186866-9 2014 Insulin secretion with sitagliptin treatment was similarly stimulated with oral and "isoglycemic" intravenous glucose. Sitagliptin Phosphate 23-34 insulin Homo sapiens 0-7 25332771-8 2014 LEARNING POINTS: The use of insulin-dose-adjusted HbA1c constitutes the best way to define partial remission in T1DM patients.The use of sitagliptin in T1DM patients could help to decrease daily requirement of insulin by delaying beta-cell loss and improving endogenous insulin production.The determination of antibodies against insulin, islet cells, and GAD permits differentiation of T1DM patients from those with atypical or ketosis-prone diabetes. Sitagliptin Phosphate 137-148 insulin Homo sapiens 28-35 25332771-8 2014 LEARNING POINTS: The use of insulin-dose-adjusted HbA1c constitutes the best way to define partial remission in T1DM patients.The use of sitagliptin in T1DM patients could help to decrease daily requirement of insulin by delaying beta-cell loss and improving endogenous insulin production.The determination of antibodies against insulin, islet cells, and GAD permits differentiation of T1DM patients from those with atypical or ketosis-prone diabetes. Sitagliptin Phosphate 137-148 insulin Homo sapiens 210-217 25332771-8 2014 LEARNING POINTS: The use of insulin-dose-adjusted HbA1c constitutes the best way to define partial remission in T1DM patients.The use of sitagliptin in T1DM patients could help to decrease daily requirement of insulin by delaying beta-cell loss and improving endogenous insulin production.The determination of antibodies against insulin, islet cells, and GAD permits differentiation of T1DM patients from those with atypical or ketosis-prone diabetes. Sitagliptin Phosphate 137-148 insulin Homo sapiens 210-217 25332771-8 2014 LEARNING POINTS: The use of insulin-dose-adjusted HbA1c constitutes the best way to define partial remission in T1DM patients.The use of sitagliptin in T1DM patients could help to decrease daily requirement of insulin by delaying beta-cell loss and improving endogenous insulin production.The determination of antibodies against insulin, islet cells, and GAD permits differentiation of T1DM patients from those with atypical or ketosis-prone diabetes. Sitagliptin Phosphate 137-148 insulin Homo sapiens 210-217 24344941-11 2013 CONCLUSIONS: In a group of renal transplant recipients with new-onset diabetes mellitus after a transplant in whom glycemia was not controlled adequately by oral hypoglycemic agents, the addition of sitagliptin helped to achieve glycemic control similar to insulin glargine but with a marginal weight advantage. Sitagliptin Phosphate 199-210 insulin Homo sapiens 257-264 23490599-3 2013 Our data suggest that the addition of exenatide and sitagliptin decreases insulin requirements without increasing endogenous insulin production and hypoglycemic events. Sitagliptin Phosphate 52-63 insulin Homo sapiens 74-81 23782502-5 2013 The 5-h insulin total AUC increased with sitagliptin versus all other treatments and increased with sitagliptin + pioglitazone versus pioglitazone. Sitagliptin Phosphate 41-52 insulin Homo sapiens 8-15 23782502-5 2013 The 5-h insulin total AUC increased with sitagliptin versus all other treatments and increased with sitagliptin + pioglitazone versus pioglitazone. Sitagliptin Phosphate 100-111 insulin Homo sapiens 8-15 23782502-8 2013 The insulin sensitivity index (ISI), a composite index of insulin sensitivity, improved with pioglitazone and sitagliptin + pioglitazone versus placebo. Sitagliptin Phosphate 110-121 insulin Homo sapiens 4-11 23782502-8 2013 The insulin sensitivity index (ISI), a composite index of insulin sensitivity, improved with pioglitazone and sitagliptin + pioglitazone versus placebo. Sitagliptin Phosphate 110-121 insulin Homo sapiens 58-65 25231694-8 2014 Adding sitagliptin to BOT in Japanese T2DM patients appears to improve glycemic control without increasing endogenous insulin secretion and to reduce fasting and 2-hour postprandial PI/C-peptide ratios. Sitagliptin Phosphate 7-18 insulin Homo sapiens 182-184 23877988-6 2013 The total daily insulin dose and number of insulin injections were significantly less in the sitagliptin groups compared with the basal bolus group (both P < 0.001). Sitagliptin Phosphate 93-104 insulin Homo sapiens 16-23 23877988-6 2013 The total daily insulin dose and number of insulin injections were significantly less in the sitagliptin groups compared with the basal bolus group (both P < 0.001). Sitagliptin Phosphate 93-104 insulin Homo sapiens 43-50 23736544-1 2013 The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin is an attractive therapy for diabetes, as it increases insulin release and may preserve beta-cell mass. Sitagliptin Phosphate 45-56 insulin Homo sapiens 112-119 23736544-2 2013 However, sitagliptin also increases beta-cell release of human islet amyloid polypeptide (hIAPP), the peptide component of islet amyloid, which is cosecreted with insulin. Sitagliptin Phosphate 9-20 insulin Homo sapiens 163-170 23413771-4 2013 Fasting plasma insulin and homeostasis model assessment of insulin resistance were significantly increased by triple therapy with glibenclamide and decreased by that with sitagliptin. Sitagliptin Phosphate 171-182 insulin Homo sapiens 15-22 23413771-4 2013 Fasting plasma insulin and homeostasis model assessment of insulin resistance were significantly increased by triple therapy with glibenclamide and decreased by that with sitagliptin. Sitagliptin Phosphate 171-182 insulin Homo sapiens 59-66 23413771-6 2013 Fasting plasma proinsulin was not influenced by triple oral therapy including glibenclamide, while it was decreased by the therapy including sitagliptin compared to glibenclamide. Sitagliptin Phosphate 141-152 insulin Homo sapiens 15-25 23386390-9 2013 Stratified analysis based on the insulin regimen revealed a stronger antidiabetic effect and a high efficacy of sitagliptin when it was added to basal insulin therapy. Sitagliptin Phosphate 112-123 insulin Homo sapiens 33-40 23433601-12 2013 The LX4211 + sitagliptin combination was associated with significantly increased active GLP-1, total GLP-1, and total PYY; with a significant reduction in total GIP; and with a significantly improved blood glucose level, with less insulin, compared with sitagliptin monotherapy. Sitagliptin Phosphate 13-24 insulin Homo sapiens 231-238 23402316-0 2013 Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy. Sitagliptin Phosphate 33-44 insulin Homo sapiens 139-146 23402316-2 2013 In this study, we investigated whether sitagliptin might provide similar benefits in type 2 diabetes patients receiving insulin therapy by using CGM. Sitagliptin Phosphate 39-50 insulin Homo sapiens 120-127 23402316-6 2013 RESULTS: The add-on treatment with sitagliptin led to significant decreases in 24-h mean glucose levels and SDs of 288 glucose levels measured by CGM for 24 h, as well as in the indices for magnitude of glucose variability and proportion of time in hyperglycemia, compared with insulin therapy alone (P<0.01), whereas there was no significant change seen in regard to the proportion of time in hypoglycemia with or without add-on treatment with sitagliptin. Sitagliptin Phosphate 35-46 insulin Homo sapiens 278-285 23402316-8 2013 In contrast, add-on sitagliptin was shown to narrow the range of 24-h glucose fluctuations in these patients, suggesting that add-on treatment with sitagliptin is effective for postprandial glucose control in type 2 diabetes patients receiving insulin therapy. Sitagliptin Phosphate 148-159 insulin Homo sapiens 244-251 23427864-6 2013 Fasting plasma insulin level and the homeostasis model assessment insulin resistance index were significantly increased by triple therapy with glibenclamide and decreased by the one with sitagliptin. Sitagliptin Phosphate 187-198 insulin Homo sapiens 15-22 23427864-6 2013 Fasting plasma insulin level and the homeostasis model assessment insulin resistance index were significantly increased by triple therapy with glibenclamide and decreased by the one with sitagliptin. Sitagliptin Phosphate 187-198 insulin Homo sapiens 66-73 23427864-8 2013 The fasting plasma proinsulin level was decreased by sitagliptin. Sitagliptin Phosphate 53-64 insulin Homo sapiens 19-29 23386390-0 2013 Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. Sitagliptin Phosphate 40-51 insulin Homo sapiens 81-88 23386390-5 2013 The hemoglobin A1c (HbA1c) of all patients improved significantly from 8.1 +- 1.2% to 7.6 +- 1.1% after 12 weeks of add-on therapy with sitagliptin (p<0.01), and the insulin dosage was reduced from 27.3 +- 15.8 U/day to 24.5 +- 16.5 U/day (p<0.001). Sitagliptin Phosphate 136-147 insulin Homo sapiens 169-176 23574730-5 2013 After 10 weeks of treatment, miglitol (n = 16) and sitagliptin (n = 18) caused a similarly significant decrease in hemoglobin A1c (mean: 7.6% to 7.3% versus 8.0% to 7.6%) and a significant increase in fasting insulin levels, with a greater increase observed in the miglitol group than in the sitagliptin group (p=0.03). Sitagliptin Phosphate 51-62 insulin Homo sapiens 209-216 22982177-8 2013 Treatments with GLP-1, exenatide, glyburide, nateglinide and sitagliptin effectively increased plasma human C-peptide levels and improved postprandial glucose concentrations. Sitagliptin Phosphate 61-72 insulin Homo sapiens 108-117 23439744-1 2013 BACKGROUND: Sitagliptin has been proven to be effective and safe as add-on to insulin in adult patients with type 2 diabetes and absolute insulin deficiency. Sitagliptin Phosphate 12-23 insulin Homo sapiens 78-85 23386390-9 2013 Stratified analysis based on the insulin regimen revealed a stronger antidiabetic effect and a high efficacy of sitagliptin when it was added to basal insulin therapy. Sitagliptin Phosphate 112-123 insulin Homo sapiens 151-158 23386390-10 2013 The results of this investigation confirmed that add-on therapy with sitagliptin to various insulin regimens could improve glycemic control without severe hypoglycemia and/or weight gain. Sitagliptin Phosphate 69-80 insulin Homo sapiens 92-99 23054692-3 2012 Sitagliptin lowers blood glucose through an insulin-dependent mechanism of action. Sitagliptin Phosphate 0-11 insulin Homo sapiens 44-51 23055336-5 2012 Compared to insulin alone, early postprandial increments in plasma C-peptide levels and suppressed glucagon levels were observed when sitagliptin was added. Sitagliptin Phosphate 134-145 insulin Homo sapiens 12-19 23055336-5 2012 Compared to insulin alone, early postprandial increments in plasma C-peptide levels and suppressed glucagon levels were observed when sitagliptin was added. Sitagliptin Phosphate 134-145 insulin Homo sapiens 67-76 23055336-8 2012 GIP levels decreased when sitagliptin or miglitol, or both, were added to insulin therapy. Sitagliptin Phosphate 26-37 insulin Homo sapiens 74-81 23055336-9 2012 CONCLUSION: The authors showed that the addition of sitagliptin or miglitol, or both, was effective in this insulin-treated patient with diabetes who had undergone gastrectomy. Sitagliptin Phosphate 52-63 insulin Homo sapiens 108-115 23061989-0 2012 A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and beta-cell function. Sitagliptin Phosphate 64-75 insulin Homo sapiens 86-93 23061989-7 2012 CONCLUSION: When metformin alone is not enough to reach an adequate glycemic control, sitagliptin can be a valid option, because of its effects in reducing insulin resistance and in preserving beta-cell function. Sitagliptin Phosphate 86-97 insulin Homo sapiens 156-163 22443183-12 2012 CONCLUSIONS: Compared to a 25% increase in insulin dose, adding sitagliptin to an insulin-based regimen was more effective at lowering HbA1c and associated with less hypoglycaemia and weight gain over 24 weeks. Sitagliptin Phosphate 64-75 insulin Homo sapiens 82-89 22682949-1 2012 AIMS: To evaluate the impact on glycemic control, insulin resistance, and insulin secretion of sitagliptin+metformin compared to metformin in type 2 diabetic patients. Sitagliptin Phosphate 95-106 insulin Homo sapiens 74-81 22682949-6 2012 Sitagliptin+metformin, but not placebo+metformin, decreased FPPr, FPPR/FPI ratio, and increased C-peptide values, even if no differences between the groups were recorded. Sitagliptin Phosphate 0-11 insulin Homo sapiens 96-105 22059736-9 2012 A greater reduction in the fasting proinsulin/insulin ratio and a greater increase in homeostasis model assessment of beta-cell function (HOMA-beta) were observed with sitagliptin/metformin than with pioglitazone, while greater decreases in fasting insulin and HOMA of insulin resistance (HOMA-IR), and a greater increase in quantitative insulin sensitivity check index (QUICKI) were observed with pioglitazone than with sitagliptin/metformin. Sitagliptin Phosphate 168-179 insulin Homo sapiens 46-53 22738299-8 2012 Sitagliptin reduced plasma glucagon between 75 and 120 min (P < 0.05), and increased intact GLP-1 (P = 0.0002) and intact GIP (P = 0.0001) by approximately twofold, but reduced total GIP (P = 0.0003) and had no effect on total GLP-1 (P = 0.16) or insulin (P = 0.75). Sitagliptin Phosphate 0-11 insulin Homo sapiens 250-257 22685234-12 2012 CONCLUSIONS: Chronic sitagliptin treatment improves glycemic control by lowering the appearance of oral glucose, postprandial endogenous glucose release, and glucagon response, and by improving insulin sensitivity and beta-cell glucose sensing in response to both oral and iv glucose. Sitagliptin Phosphate 21-32 insulin Homo sapiens 194-201 22512606-0 2012 Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes. Sitagliptin Phosphate 0-11 insulin Homo sapiens 117-124 22512606-1 2012 AIMS: To assess the efficacy and safety of combination therapy with sitagliptin and low dosage sulphonylureas on glycaemic control and insulin secretion capacity in Japanese type 2 diabetes. Sitagliptin Phosphate 68-79 insulin Homo sapiens 135-142 22512606-16 2012 Glucagon loading test indicated that 1 year administration of sitagliptin and sulphonylureas preserved insulin secretion capacity. Sitagliptin Phosphate 62-73 insulin Homo sapiens 103-110 22949894-7 2012 These findings indicate that sitagliptin may improve insulin resistance and steatosis in patients with refractory NAFLD. Sitagliptin Phosphate 29-40 insulin Homo sapiens 53-60 22059736-9 2012 A greater reduction in the fasting proinsulin/insulin ratio and a greater increase in homeostasis model assessment of beta-cell function (HOMA-beta) were observed with sitagliptin/metformin than with pioglitazone, while greater decreases in fasting insulin and HOMA of insulin resistance (HOMA-IR), and a greater increase in quantitative insulin sensitivity check index (QUICKI) were observed with pioglitazone than with sitagliptin/metformin. Sitagliptin Phosphate 168-179 insulin Homo sapiens 35-45 22059736-9 2012 A greater reduction in the fasting proinsulin/insulin ratio and a greater increase in homeostasis model assessment of beta-cell function (HOMA-beta) were observed with sitagliptin/metformin than with pioglitazone, while greater decreases in fasting insulin and HOMA of insulin resistance (HOMA-IR), and a greater increase in quantitative insulin sensitivity check index (QUICKI) were observed with pioglitazone than with sitagliptin/metformin. Sitagliptin Phosphate 168-179 insulin Homo sapiens 38-45 22059736-9 2012 A greater reduction in the fasting proinsulin/insulin ratio and a greater increase in homeostasis model assessment of beta-cell function (HOMA-beta) were observed with sitagliptin/metformin than with pioglitazone, while greater decreases in fasting insulin and HOMA of insulin resistance (HOMA-IR), and a greater increase in quantitative insulin sensitivity check index (QUICKI) were observed with pioglitazone than with sitagliptin/metformin. Sitagliptin Phosphate 168-179 insulin Homo sapiens 46-53 21923696-7 2011 RESULTS: Sitagliptin significantly reduced blood glucose (2-h postprandial and 24-h area under the curve) despite reduced total and prandial insulin dose. Sitagliptin Phosphate 9-20 insulin Homo sapiens 141-148 22059736-9 2012 A greater reduction in the fasting proinsulin/insulin ratio and a greater increase in homeostasis model assessment of beta-cell function (HOMA-beta) were observed with sitagliptin/metformin than with pioglitazone, while greater decreases in fasting insulin and HOMA of insulin resistance (HOMA-IR), and a greater increase in quantitative insulin sensitivity check index (QUICKI) were observed with pioglitazone than with sitagliptin/metformin. Sitagliptin Phosphate 168-179 insulin Homo sapiens 46-53 21923696-10 2011 After controlling for period, treatment and insulin dose, the HbA(1c) was also significantly reduced [-0.27 +- 0.11% (-2.91 +- 1.16 mmol/mol); P = 0.025] when patients were taking sitagliptin. Sitagliptin Phosphate 180-191 insulin Homo sapiens 44-51 21923696-11 2011 CONCLUSIONS: Sitagliptin significantly improved overall glucose control, including postprandial and 24-h glucose control, in adult patients with Type 1 diabetes, while significantly reducing prandial insulin requirements. Sitagliptin Phosphate 13-24 insulin Homo sapiens 200-207 21410627-6 2011 Homeostasis model assessment of beta-cell function (HOMA-beta) and fasting proinsulin/insulin ratio were significantly improved with sitagliptin/metformin FDC versus metformin monotherapy. Sitagliptin Phosphate 133-144 insulin Homo sapiens 75-85 21410627-6 2011 Homeostasis model assessment of beta-cell function (HOMA-beta) and fasting proinsulin/insulin ratio were significantly improved with sitagliptin/metformin FDC versus metformin monotherapy. Sitagliptin Phosphate 133-144 insulin Homo sapiens 78-85 21226820-8 2011 Sitagliptin therapy also improved homeostasis model assessment (HOMA) index for insulin resistance (-14.6%, p = 0.01) and beta-cell function (+32.3%, p = 0.007). Sitagliptin Phosphate 0-11 insulin Homo sapiens 80-87 21226820-9 2011 CONCLUSIONS: Treatment with sitagliptin for 6 weeks reduced postprandial plasma levels of TG-rich lipoproteins of both intestinal and hepatic origin, most likely by increasing incretin hormone levels, reducing circulating plasma FFA concentrations and improving insulin sensitivity and beta-cell function. Sitagliptin Phosphate 28-39 insulin Homo sapiens 262-269 21738898-1 2011 BACKGROUND: Sitagliptin is a highly selective dipeptidyl peptide-4 (DPP-4) inhibitor that increases blood levels of active glucagon-like peptide (GLP)-1 and glucose-dependent insulinotrophic polypeptide (GIP), resulting in increased insulin secretion. Sitagliptin Phosphate 12-23 insulin Homo sapiens 175-182 21443773-10 2011 CONCLUSION: This report demonstrates that sitagliptin is effective and safe as an add-on therapy to insulin in reducing blood glucose levels in patients who absolutely lack the capacity for endogenous insulin secretion. Sitagliptin Phosphate 42-53 insulin Homo sapiens 100-107 21443773-10 2011 CONCLUSION: This report demonstrates that sitagliptin is effective and safe as an add-on therapy to insulin in reducing blood glucose levels in patients who absolutely lack the capacity for endogenous insulin secretion. Sitagliptin Phosphate 42-53 insulin Homo sapiens 201-208 20015525-11 2010 The addition of both sitagliptin or metformin to pioglitazone gave an improvement of HbA(1c), FPG, and PPG; but metformin led also to a decrease of body weight and to a faster and better improvement of insulin resistance and inflammatory state parameters, even if sitagliptin produced a better protection of beta-cell function. Sitagliptin Phosphate 21-32 insulin Homo sapiens 202-209 21175268-1 2011 BACKGROUND: this study reports on the effectiveness of sitagliptin in Asian Indian type 2 diabetes patients seen at a tertiary diabetes care center who had inadequate glycemic control with oral hypoglycemic agents either alone or in combination, compared to a group of patients who received insulin glargine. Sitagliptin Phosphate 55-66 insulin Homo sapiens 291-298 21175268-8 2011 CONCLUSIONS: in a large group of Asian Indian type 2 diabetes patients seen at a tertiary diabetes center in whom glycemia was not controlled adequately by oral hypoglycemic agents (either alone or in combination), addition of sitagliptin helped to achieve glycemic control to a similar extent as insulin glargine but with a marginal weight advantage. Sitagliptin Phosphate 227-238 insulin Homo sapiens 297-304 21437106-3 2010 Complementary combination therapy with sitagliptin-metformin lowers glucose via enhancement of insulin secretion, suppression of glucagon secretion, and insulin sensitization. Sitagliptin Phosphate 39-50 insulin Homo sapiens 95-102 21189532-4 2010 Janumet is a fixed-dose combination of sitagliptin, a specific inhibitor of dipeptidylpeptidase-4 that blocks the rapid degradation of so-called incretin hormones (resulting in a potentiation of insulin secretion and reduction of glucagon secretion in a glucose-dependent manner), and of metformin, a biguanide compound that reduces glucose hepatic production and slightly improves insulin sensitivity. Sitagliptin Phosphate 39-50 insulin Homo sapiens 195-202